These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15651260)

  • 1. Monitoring participant safety in phase I and II interventional trials: options and controversies.
    Hibberd PL; Weiner DL
    J Investig Med; 2004 Nov; 52(7):446-52. PubMed ID: 15651260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
    Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
    Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Building a more connected DSMB: better integrating ethics review and safety monitoring.
    Eckstein L
    Account Res; 2015; 22(2):81-105. PubMed ID: 25397600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing a data and safety monitoring plan.
    Slimmer L; Andersen B
    West J Nurs Res; 2004 Nov; 26(7):797-803. PubMed ID: 15466615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data and safety monitoring during randomized controlled trials of nursing interventions.
    Artinian NT; Froelicher ES; Vander Wal JS
    Nurs Res; 2004; 53(6):414-8. PubMed ID: 15586138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forming your phase III trial's data and safety monitoring board: a perspective on safety.
    Wittes J
    J Investig Med; 2004 Nov; 52(7):453-8. PubMed ID: 15651261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating and implementing data and safety monitoring plans.
    Terrin ML
    J Investig Med; 2004 Nov; 52(7):459-63. PubMed ID: 15651262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent data and safety monitoring in psychiatric intervention research.
    Leon AC
    J Clin Psychiatry; 2012 Feb; 73(2):e257-63. PubMed ID: 22401486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review.
    Gewandter JS; Kitt RA; Hunsinger MR; Poku J; Lozano J; Chaudari J; Evans S; Gross RA; McDermott MP; Rowbotham MC; Turk DC; Dworkin RH
    J Clin Epidemiol; 2017 Mar; 83():101-107. PubMed ID: 28126598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
    [No Abstract]   [Full Text] [Related]  

  • 13. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees.
    ; Dixon DO; Freedman RS; Herson J; Hughes M; Kim K; Silverman MH; Tangen CM
    Clin Trials; 2006; 3(3):314-9. PubMed ID: 16895048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the data safety and monitoring board in an international trial.
    NIMH Collaborative HIV/STD Prevention Trial
    AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardization, more funds on horizon for clinical trials.
    McNeil C
    J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874
    [No Abstract]   [Full Text] [Related]  

  • 16. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to improve the clinical development paradigm and its division into phases I, II and III.
    Bamberger M; Moore N; Lechat P;
    Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [DSMB. 2. The importance of an efficient DSMB: some examples of high-risk clinical trials].
    Brun-Buisson C
    Med Sci (Paris); 2005 Feb; 21(2):187-9. PubMed ID: 15691491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.